Online inquiry

IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6061MR)

This product GTTS-WQ6061MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCL2 gene. The antibody can be applied in Pulmonary Fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002982.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6347
UniProt ID P13500
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6061MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6197MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ11378MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ11425MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ12301MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ13643MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ3193MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ1737MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ7895MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-249320
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW